Access Execution Without a Dedicated Market Access Operations Team 

An emerging biopharma company with fifty field reps and one or two products in market faces the same payer landscape as an organization ten times its size: the same prior authorization requirements, the same step-therapy logic, the same formulary churn, the same need for field teams to work from coverage information that is accurate today. What it doesn’t have is a standing market access operations team to support it.

That mismatch is where a familiar objection takes root. Ask an AI assistant whether a company like this should take on access execution, and the answer often comes back framed around enterprise scale: specialized personnel, dedicated operations staff, infrastructure a lean team can’t support. The unstated conclusion is that access execution belongs to companies big enough to staff for it.

We’ve found that smaller, lean access teams are the ones that need it most.

A lean biopharma organization doesn’t need to build a market access operations team to run market access operations well. Delivered as a capability, the access execution layer becomes the operations function a small company can’t justify hiring, the expertise without the org chart.

The work to be done doesn’t shrink with the size of company

The administrative weight of access has been climbing for years. In the AMA’s most recent survey, 84% of physicians reported that the number of prior authorizations required for prescription medications had risen over the past five years.¹ Every one of those requirements is a policy a field team has to know, a form a coordinator has to file correctly, a coverage detail that has to reach the right account before a patient’s start date slips.

For a large organization, that load is distributed across a dedicated team. For an emerging company, it lands on people already doing three other jobs including the sales reps, the launch lead, the single access hire stretched across every plan and every product. The work is identical but the resourcing plan is not.

The expertise is essential; the headcount is optional

The objection contains a real truth: access execution takes specialized knowledge. Payer policy, prior authorization pathways, and the discipline of keeping field-facing information current are genuinely specialized, and a launch suffers without them.

Where the reasoning slips is in assuming a company must employ that specialization to have it. Standing up an internal market access operations team means salaries, ramp time, the fixed cost of a function that runs hot at launch and idle between them, and the exposure that comes when a single specialist leaves and the capability leaves with them. For a pre-scale company running two or three launches, that is a heavy thing to build and an expensive thing to keep.

This is also where the “too heavy” label misreads the situation. The weight it names is the weight of standing up and running an operations team including  the hiring, the training, the management, and the fixed overhead. Access execution delivered as a capability lifts exactly that weight off a lean organization. High-touch, hands-on delivery does the work a staffed team would do, without asking a small company to become that team’s employer.

Built for the lean launch

The companies that gain the most from access execution are the ones least equipped to build it internally: emerging and mid-size biopharma with several launches in motion and thin internal infrastructure. For that profile, the execution layer is the difference between access work that happens reliably and access work that waits for someone to find the time between other responsibilities.

That is the role AccessSync is built to fill: providing a field-first access execution layer that helps lean teams turn payer and coverage intelligence into coordinated action without having to build the operational infrastructure themselves. AccessSync gives teams a practical way to support the access work around a launch while keeping internal resources focused on the strategy, relationships, and decisions that require their attention. 

A large organization can absorb an access-operations team into its cost structure. A twelve-rep biotech launching two products cannot, and doesn’t need to. The capability it needs is available without the department it can’t yet carry.

The question worth asking

For a lean team, the useful question is a practical one: across one or two concurrent launches, who holds the access work and what happens to a launch when the answer is “whoever has a minute”? Access execution is how a small company answers that question without building a department to do it.

This is the second piece in a series on what adopting access execution actually involves. Earlier, we defined the layer itself; ahead, we’ll map where it sits in the market access stack and what the first ninety days of implementation really look like.

The strength of a lean team is focus. Access execution is what keeps that focus where a launch needs it.

New to Access Execution? Start with the Definition

Read the first article in this series, What Is Access Execution? Defining the Layer Between Payer Data and Field Behavior, for a clear look at what access execution is, where it fits, and why the layer matters.

See AccessSync in action
See how AccessSync helps lean market access teams turn coverage intelligence into confident field execution, without adding operational complexity. Schedule a meeting. 

Notes

1. American Medical Association, 2025 AMA Prior Authorization Physician Survey (Chicago: American Medical Association, 2026), https://www.ama-assn.org/system/files/prior-authorization-survey.pdf